89SrCl联合依班膦酸钠治疗多发性骨转移癌疼痛

目的 观察89SrCl2联合依班膦酸钠治疗多发性骨转移癌疼痛与单独应用依班膦酸钠或89SrCl2治疗的临床疗效。方法84例骨转移癌疼痛患者，分为3个治疗组，其中30例采用89SrCl，联合依班膦酸钠方法，26例采用单纯89SrCl2治疗，28例采用依班膦酸钠治疗。用SPSS13．0统计软件，疗效比较采用行×列表资料的r检验。结果联合治疗组骨痛缓解总有效率为96．6％（29／30），依班膦酸钠组及89SrCl2治疗组总有效率分别为71．4％（20／28）和73．1％（19／26）。联合用药组与单独用药组治疗后骨痛缓解有效率（X2=7．497），全身状况Kamofsky评分提高率80．0％（24／30）与50．0％（14／28），53．8％（14／26）,X2=35．476]和病灶治疗有效率47．6％（50／105）与11．2％（11／98），22．2％（20／90）,X2=6．564]间比较差异有统计学意义（P均〈0．05）。结论89SrCl2联合依班膦酸钠是治疗骨转移性癌疼痛较为有效和可行的方法。联合用药临床疗效优于单独用药。

Treatment with 89SrCl and Sodium Ibandronate for pain relief of multiple bone metastases

Objective To evaluate the palliative effect on pain relief in patients with multiple bone metastases treated with 89SrCl2 together with Sodium Ibandronate,Sodium Ibandronate alone and 89SrCl2 alone. Methods Eighty-four patients with bone pain secondary to bone metastases were divided into three groups. Thirty patients were treated with combined 89SrCl2 and Sodium Ibandronate,26 with 89SrCl2 alone and 28 with Sodium Ibandronate alone. The x2 test was used in data analysis. Results The overall palliative pain relief rate in the combined treatment group was 96.6 % (29/30). For the groups using Sodium Ibandronate or 89SrCl2 only,the palliative rates were 71.4% (20/28) and 73.1% (19/26),respectively. There are statistically significant differences between the combined treatment group and the other 2 groups with single treatment modalities in the overall palliative pain relief rate (x2 = 7.497 ),in terms of improvement in (1) whole body Karnofsky performance status (KPS) score (80.0% (24/30) vs 50.0% (14/28)/53.8% (14/26),x2 =35.476) and (2) focal palliative rate (47.6% (50/105) vs 11.2% (11/98)/22.2% (20/90),x2 =6. 564,all P ＜ 0. 05 ). Conclusions Combined treatment with 89 SrCl2 and Sodium Ibandronate is more effective than single treatment modalities to relieve bone pain seccondary to multiple bone metastases.